BioPharma Clinical Trials
R520A is an mRNA COVID-19 vaccine specifically targeting the Omicron variant developed by Wuhan Recogen Biotechnology Co., Ltd., a subsidiary of the Compan...
June 28, 2022 | News
Selinexor is an oral small molecule XPO1 inhibitor; tislelizumab is an anti-PD-1 checkpoint inhibitor Antengene Corporation Limited ("...
June 27, 2022 | News
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients Priority Review requested; if accepted, anticipate an 8-mont...
June 23, 2022 | News
New research in the June 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network raises issues with clinical tri...
June 22, 2022 | News
WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO), and Wugen Inc., a clinical-stage biotech...
June 16, 2022 | News
Evonik now offers a highly pure cystine peptide to address challenges in the formulation of cell culture media and processes used in the development and pr...
June 07, 2022 | News
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative im...
June 07, 2022 | News
Contributing to this collaboration, Delta 4 will apply its proprietary computational and iterative big data analytics platform to identify novel therapeuti...
June 03, 2022 | News
This Phase 2 clinical trial (double-blind, placebo-controlled) aims to evaluate the efficacy of UB-221 as a long-acting add-on therapy for treatment of chr...
May 31, 2022 | News
Encouraging efficacy signals were observed in a non-small cell lung cancer (NSCLC) patient cohort - Results indicate CD73 expression corr...
May 27, 2022 | News
The 2022 CSCO Guidelines incorporate a total of four selinexor combination therapy regimens for relapsed myeloma. In addition, the guidelines also recommen...
May 13, 2022 | News
As disclosed in the prospectus of the Company dated March 21, 2022, the Group had initiated subject enrollment for the phase II/III clinical trial for...
May 06, 2022 | News
IMG-007 is highly potent at blocking the binding of OX40 to OX40L, thereby reducing OX40L-dependent downstream signaling and cytokine release by T cells. I...
May 02, 2022 | News
IQVIA Institute releases report on Lessons Learned from COVID-19 Vaccine Trials Solutions for you to dri...
April 28, 2022 | News
Most Read
Bio Jobs
News
Editor Picks